Grants for Small businesses - Federal

This funding opportunity supports institutions in developing training programs for predoctoral and postdoctoral researchers focused on advancing knowledge and skills in aging research, aiming to prepare a diverse group of scientists for careers in this critical field.

The purpose of this funding opportunity is to develop artificial intelligence tools and experimental assays to identify new pharmacotherapeutics with lower toxicity and higher efficacy for substance use disorders (SUD) Areas of interest include but are not limited to: 1) Development of AI tools to identify potential target combinations, design new molecules, conduct virtual preclinical studies to predict efficacy and toxicity, and model in vitro and in vivo polypharmacology 2) Development of assays to assess the effects of compounds on multiple targets or functions

The USDA SBIR/STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental research, the USDA SBIR/STTR programs support small businesses in the creation of innovative, disruptive technologies and enable the application of research advancements from conception into the market. The STTR program aims to foster technology transfer through formal cooperative R between small businesses and nonprofit research institutions.

The National Bycatch Reduction Engineering Program (BREP) - FY2025 aims to fund innovative research and development projects that reduce bycatch of non-target species in fisheries, promoting sustainable practices and protecting marine ecosystems.

The DoD Kidney Cancer, Academy of Kidney Cancer Investigators - Early-Career Scholar Award is a grant aimed at supporting early-career scholars in conducting kidney cancer research, providing them with funding, networking, and collaborative opportunities, and mentorship for a period of four years, with the ultimate goal of advancing kidney cancer research and developing highly productive kidney cancer researchers.

This funding opportunity supports innovative research and development in biological technologies that enhance national security, targeting universities, nonprofits, small businesses, and industry participants, particularly those with commercial potential.

The National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) with other NIH Institutes and Centers (ICs), intends to publish a new Notice of Funding Opportunity (NOFO) to solicit applications for multi-PI team-based, challenging, high impact projects to improve understanding of mechanisms of chronic pain in children and adolescents and to accelerate the development of age appropriate, patient/family centered prevention and therapeutic approaches. This research will seek to advance an integrated understanding of the biological, psychological, and social factors that contribute to pediatric chronic pain. NIH is interested in pain research in infants, children, and adolescents that includes those with intellectual and physical disabilities and/or those who experience health disparities (e.g., diverse race/ethnicity, sexual and gender minorities, socioeconomically disadvantaged, medically underserved communities, people with limited English proficiency). NIH encourages applicants to consider community-engaged research and interdisciplinary, collaborative applications to be developed in partnership with patient communities and/or community organizations where possible. The long-term goal is to develop improved knowledge of specific pediatric pain conditions as well as pain associated with diverse diseases/disorders, to improve understanding of pain in the context of child development and to facilitate the stratification of patients with specific pain conditions and co-morbidities to accelerate chronic pain prevention and therapeutic clinical trials. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in May 2024 with an expected application due date in Fall 2024. This NOFO will utilize the UC2 Research Project Cooperative Agreements activity code. Details of the planned NOFO are provided below.

The "Limited Competition: NIGMS Mature Synchrotron Resources for Structural Biology" grant aims to fund well-established structural biology resources at synchrotron facilities, with the goal of maintaining or upgrading them to current best practices, promoting their availability to the biomedical research community, and providing user training and support.

This funding opportunity provides financial support to small businesses developing new medications for treating alcohol use disorder and related organ damage, with a focus on advancing these therapies toward FDA approval.

This funding opportunity supports collaborative research projects by multidisciplinary teams focused on addressing significant challenges related to substance use disorders and their health consequences.

This funding opportunity supports small businesses in the U.S. to develop innovative solutions for diagnosing and treating health issues related to non-disordered drug use, such as complications from opioid and stimulant use.

This grant provides funding to U.S.-based small businesses to develop innovative health-related technologies that require clinical trials, with a focus on projects that align with the missions of the NIH and CDC.

This funding opportunity provides financial support to small businesses that have previously received a Phase I grant to further develop their innovative research and commercialization plans in areas aligned with NOAA's mission.

CDPs Foreign Assistance Leveraged for Cybersecurity Operational Needs FALCON project is intended to establish and maintain a reservoir of primarily commercial cybersecurity and technology capabilities that CDP can draw upon in short order and in a wide variety of situations to support U.S. allies and partners to effectively prevent, respond to, mitigate, and recover from cybersecurity incidents. The objective of the project is to support partner governments, their subordinate agencies and critical infrastructure operators and partners in their efforts to identify, prevent, respond to, mitigate and recover from cybersecurity incidents.

This funding opportunity supports U.S.-based institutions in developing innovative quantum computing solutions to significantly improve computational chemistry and materials science for energy applications.

The PRMRP Investigator-Initiated Research Award (IIRA) supports fundamental research studies that will make an important contribution toward research, patient care, and/or quality of life for a disease or condition related to one of the FY24 PRMRP Topic Areas and one of the FY24 PRMRP Strategic Goals. This award mechanism is intended to support basic research that is exploratory in nature and seeks to further or validate preliminary findings for short- or long-term impact. Research projects may focus on any stage of basic laboratory research, ranging from fundamental research for the generation of knowledge, hypothesis, or models, to expansion of mature data.The rationale for a research idea may be derived from a laboratory discovery, population-based studies, a clinicians first-hand knowledge of patients, or anecdotal data. The project should include a well-formulated testable hypothesis based on existing evidence. Applications must include relevant preliminary data that support the rationale and feasibility for the proposed study. These data may be unpublished or from the published literature.This award mechanism is not intended to support translational research. Applicants seeking funding for projects that have progressed beyond the realm of basic research should consider one of the other FY24 PRMRP program announcements being offered. For information about these award mechanisms, see Section II.A.1, FY24 PRMRP Research Development Pipeline.

The "Promoting a Just Transition for All Workers" grant is currently being developed to support fair changes in the workforce, with updates and further details to be provided via the Grants.gov subscription service.

The key aspects of this award are: Overarching Question: FPA-RM applications must describe a unifying, overarching question that will be investigated by a set of research projects to address a critical unmet need relevant to rare melanoma research and/or patient care. The question may focus on one specific rare melanoma, or the question may be designed to address a critical unmet need that is relevant to multiple rare melanomas. Research Team: The overall effort will be led by a Principal Investigator (PI) with demonstrated success in leading large, focused projects. The PI is required to devote a minimum of 10% effort to this award. The PI will be the lead for one of the proposed research projects and is expected to create an environment that fosters and supports collaboration and innovation in a way that engages all members of the team. The research team assembled by the PI should be highly qualified and multidisciplinary, with an identified Project Leader(s) for the complementary and synergistic research project(s). The resources and expertise brought to the team by the Project Leader(s) should combine to create a robust collaboration. The PI and the Project Leader(s) do not have to be at the same organization. Research Projects: Applications should include multiple, distinct research projects that are each led by individual Project Leaders and address complementary aspects of the overarching question. Individual research projects may range from exploratory, hypothesis-developing studies through clinical trials. While individual projects should be capable of standing on their own high scientific merits, they should also be interrelated and synergistic to advance a solution beyond what would be possible through individual efforts. Each project, including hypothesis-developing studies, should propose a unique approach to addressing the overarching question and be capable of producing research findings with potential to advance the rare melanoma field and/or patient care. There should be a clear intent to progress toward translational/clinical work over the course of the effort. This award mechanism is not intended to support a series of research projects that are dependent on the success of the other project(s). All research projects must be based on a strong scientific rationale and preliminary data, as appropriate, that supports the feasibility of the proposed approach(es). Clinical trials are allowed; a research project proposing a clinical trial must include preliminary data. Implementation Plan: The research strategy to address the overarching question should be supported by an implementation plan that identifies critical milestones and outlines the knowledge, resources, and/or technical innovations that will be utilized to achieve the milestones. A plan for assessing individual project performance and progress toward addressing the overarching question should be included in the implementation plan. For multi-institutional collaborations, the application should discuss plans for communication and data transfer among the collaborating institutions, as well as how data, specimens, and/or products obtained during the study will be handled. Participating organizations should formalize an intellectual and material property plan. Milestone Meeting: The PI will be required to present an update on progress toward accomplishing the goals of the award at a Milestone Meeting to be held either virtually or in person in the National Capital Area after the conclusion of year 2 of the period of performance. The intent of the Milestone Meeting is to assess research progress, address problems, and define future directions. Research milestones to be accomplished by the end of year 2 must be clearly defined in the Statement of Work (SOW) and will be finalized during award negotiations. Up to two additional members of the research team may be invited to the meeting. If the research team includes rare melanoma consumer collaborators (see below), they should also be invited to attend the Milestone Meeting. The Milestone Meeting will be attended by members of the MRP Programmatic Panel, CDMRP staff, the USAMRAA Grants Officer, and other Department of Defense (DOD) stakeholders. Continued funding may be contingent upon the successful completion of specific research milestones and goals.

This funding opportunity supports research on non-invasive brain stimulation techniques to better understand and treat substance use disorders by exploring their effects on cognitive and neurobiological processes in humans.

This funding opportunity provides financial support to organizations aiming to improve healthcare services and operational efficiency in rural healthcare facilities across the Delta region.